Madrigal buys into GLP-1 from CSPC; Apellis wins expanded drug approval

Hong Kong-based CSPC will receive $120 million from Madrigal under the deal. Elsewhere, Apellis and PTC Therapeutics won FDA approvals.

By Ned Pagliarulo • July 30, 2025

Bain leads $300M investment in startup built on Bristol Myers immune drugs

Bristol Myers will get a nearly 20% stake in the startup, which will be led by one of its former executives and advance five drugs that no longer fit its plans.

By Ben Fidler • July 29, 2025

Explore the Trendline➔

Cell therapy

The continued emergence of CAR-T therapy has fueled research into next-generation approaches and new applications, such as its use in autoimmune diseases.

By BioPharma Dive staff

Radiopharma startup Artbio secures $132M to fund testing of Pluvicto rival

Led by former Novartis executive Emanuele Ostuni, the startup has a prostate cancer medicine advancing into early clinical tests and is building a manufacturing network in support.

By Gwendolyn Wu • July 29, 2025

GenAI and real-world data in pharma: 4 questions to fuel effective insights

To truly unlock the power of RWD, GenAI must go beyond checking a box or staying on trend.

By Niyati Parikh, VP, Product Readiness, Panalgo; Matt Guthrie, Director, HEOR and Medical Affairs, Panalgo • July 28, 2025

Sarepta woes mount as Duchenne gene therapy knocked back in Europe

The European Medicines Agency determined testing failed to prove Elevidys’ benefit and issued a negative opinion that could further jeopardize Sarepta’s financial future.

By Ben Fidler • Updated July 25, 2025

A TCG offshoot pulls in $400M for biotech startup creation

TCG Labs Soleil, which launched in 2024 in collaboration with The Column Group, is focused on building single-drug biotechs it can position for partnerships.

By Gwendolyn Wu • July 24, 2025

Galapagos, having backtracked on split, weighs sale of cell therapy business

A decision to possibly sell the business, which was poised to become the centerpiece of a restructuring plan, represents a shift in strategy by new company leaders.

By Kristin Jensen • July 24, 2025

Rocket lays off staff; Abivax capitalizes on immune drug data

The gene therapy developer is cutting 30% of its workforce. Elsewhere, Abivax secured a major cash infusion, while Novartis and Eli Lilly struck research deals.

By BioPharma Dive staff • July 24, 2025

[Podcast] The Progress Profile: Alzheimer’s Research in Focus

Discover the latest breakthroughs in Alzheimer's research, diagnosis, and prevention in this expert-led podcast series.

By BioPharma Dive's studioID • July 24, 2025

Abivax stock soars on trial data for ulcerative colitis drug

The French biotech is developing a new drug approach in a disease market that’s projected to grow to $30 billion by 2030.

By Kristin Jensen • July 23, 2025

Dispatch emerges with $216M and plans for a ‘universal’ solid tumor therapy

The startup is using elements of gene and cell therapy to create medicines that could be useful against an array of tough-to-treat solid tumors.

By Ben Fidler • July 23, 2025

Sanofi to acquire vaccine biotech in billion-dollar deal

The French pharma will pay $1.15 billion upfront to buy Vicebio and gain access to non-mRNA vaccine candidates against RSV and metapneumovirus.

By Delilah Alvarado • Updated July 22, 2025

Replimune drug rejected by FDA; Omega raises $647M biotech fund

Analysts questioned whether the complete response letter Replimune received was evidence of changing approval standards at the FDA.

By BioPharma Dive staff • July 22, 2025

Apples to apples: Stelara biosimilars and the fight for market share

How will payers determine which Stelara biosimilar to add to their formularies?

By Samantha Ngan, Associate Manager, Market Research, MMIT and Andrew Rouff, Senior Consultant, Advisory Services, MMIT • July 21, 2025

Bristol Myers’ Reblozyl falls short in Phase 3; Blenrep voted down by FDA panel

The anemia treatment missed its main goal in a myelofibrosis study. Meanwhile, Blenrep's return to the U.S. market may have become more difficult after the negative advisory committee vote.

By BioPharma Dive staff • July 18, 2025

Sarepta reports patient death in limb-girdle trial, compounding concerns on gene therapy risks

The death of a 51-year-old man in the study follows two other deaths of Duchenne patients treated with Sarepta’s marketed gene therapy Elevidys.

By Ben Fidler • Updated July 18, 2025

Biotech startup funding dried up in second quarter, HSBC finds

Overall venture funding, as well as “first financing” rounds, fell significantly in the second quarter, reversing 2025’s fast start, according to HSBC.

By Gwendolyn Wu • July 17, 2025

Sarepta to lay off about 500 employees after Duchenne gene therapy setbacks

On a conference call, CEO Doug Ingram said the decision to cut 36% of the company's staff and halt several drug programs was essential to ensuring Sarepta's "long-term viability."

By Ben Fidler • Updated July 16, 2025

Hengrui, Kailera say dual-acting obesity shot succeeds in China study

The results position Hengrui to seek approval of the Zepbound-like drug in China, and Kailera, a well-funded startup, to begin global late-stage testing.

By Ben Fidler • July 15, 2025

Vertex secures Alyftrek coverage in England; Merck starts Phase 3 trials of HIV drug

NHS England agreed to reimburse Vertex's newest cystic fibrosis medicine. Meanwhile, Merck advanced a once-monthly PrEP pill into late-stage trials.

By BioPharma Dive staff • July 15, 2025

FDA rejects Ultragenyx gene therapy over manufacturing concerns

While the CRL derails a near-term clearance, one analyst described the rejection as more of “a speed bump to approval, rather than a roadblock.”

By Delilah Alvarado • July 14, 2025

Jazz names new CEO; Ultragenyx, Mereo shares slide on trial update

Current operations chief Renee Gala will succeed Bruce Cozadd at Jazz. Meanwhile, Nuclidium raised about $99 million to develop radiopharmaceuticals that involve copper isotopes.

By BioPharma Dive staff • July 11, 2025

Renasant Bio, chasing drugs for ADPKD, raises $55M in seed funding

The biotech is taking inspiration from cystic fibrosis treatment and applying a similar approach to developing "corrector" and "potentiator" medicines for the kidney disease.

By Gwendolyn Wu • July 10, 2025

Gilead signs lenacapavir access deal; Arvinas CEO to step down

The drugmaker will provide, at no profit, doses to treat up to 2 million people in resource-limited countries. Meanwhile, Arvinas' John Houston is retiring from his role leading the biotech.

By BioPharma Dive staff • July 9, 2025

Actithera draws new investors to radiopharma drug pitch

The four-year-old biotech raised about $75 million in a Series A round that involved nine venture capital firms.

By Gwendolyn Wu • July 9, 2025